

11~13 October 2018
Grand Hilton Seoul Hotel, Seoul, Korea



Celebrating the 50th anniversary of the Korean Diabetes Association



•	Organization	4
•	Floor plan	5
•	Program at a glance	8
•	Scientific program	12
•	General information	46

3

47

Invitation

• Exhibition

INVITATION

Dear Diabetes researchers,

On behalf of the Korean Diabetes Association (KDA), it is our great honor to invite you to the 2018 International Congress of Diabetes and Metabolism (ICDM2018), which will take place from 11-13 October 2018, at the Grand Hilton Hotel in Seoul, Korea.

Since the first meeting in 2011, ICDM has become a leading international meeting on diabetes and metabolism in Asia. Every year, over 1,500 clinicians and scientists from dozens of countries attend ICDM to learn the latest knowledge on diabetes care, and to share the ideas on science and technology to fight against diabetes.

The scientific program of ICDM 2018 includes plenary lectures from Prof. Barbara B. Kahn (Harvard University, USA), and Prof. Philipp E. Scherer (UT Southwestern, USA). There will be more than 20 symposium sessions covering various aspect of diabetes care and research from cutting-edge basic research to up-to-date, evidence-based treatment strategies as well as clinical practice guidelines, particularly for Asian populations. Besides, there will be excellent pre- and post-Congress meetings. "Keystone symposia on Drivers of Type 2 Diabetes: From Genes to Environment" will take place right before ICDM2018 at the same venue from 7-11 October 2018. "Comprehensive education course for Asian diabetes educators" will be held right after ICDM2018 on 14th October 2018.

Thus, ICDM 2018 provides a fantastic opportunity to learn the state of the art knowledge, to share ideas and to communicate with experts in diabetes care and research.

KDA is celebrating its 50th anniversary in 2018. We welcome you to our wonderful meeting and hope you enjoy your visit as you see some of our history and achievement.

We are looking forward to seeing you in ICDM2018 this autumn.

Yours sincerely,

In-Kyu Lee, M.D., Ph.D.

President

Korean Diabetes Association



Kyong Soo Park, M.D., Ph.D. Chairman, Board of Directors Korean Diabetes Association

ORGANIZATION

Organizing committee

 Chairman Kyong Soo Park Co-Chairman In-Kyu Lee Secretary general Young Min Cho Scientific program Bong Soo Cha Publication Kyu Chang Won International liaison Sung Hee Choi Education Dong-Hyeok Cho Public relation Dae Jung Kim Treasurer Jae Hyeon Kim Auditor Kyu Jeung Ahn, Choon Hee Chung

Scientific program committee

 Chair Bong Soo Cha Secretary Byung-Wan Lee Members

Young Min Cho Sung Hee Choi SungWan Chun In-Kyung Jeong Shin Ae Kang Hae Jin Kim Hail Kim Hye Soon Kim Hyun Jin Kim Jaetaek Kim Nan Hee Kim Sang Soo Kim Sang Yong Kim Eun Hee Koh Dae Ho Lee Hye Jin Lee Yong-ho Lee Jung Hyun Noh Cheol-Young Park Keun-Gyu Park Tae Seo Sohn Jong Chul Won

Local advisory board

 Members Hong-Sun Baek Dong Seop Choi

Young Kil Choi Min Young Chung Kap Bum Huh Sung Koo Kang Bo Wan Kim Jin Woo Kim Kwang Won Kim Sun Woo Kim Tae Wha Kim Young Kun Kim Yong Ki Kim Young Seol Kim Hong Kyu Lee Hyun Chul Lee Hyun Chul Lee Sung Woo Park Soon Hyun Shinn

Ho Young Son

Bong Yun Cha

Hyung Joon Yoo

International advisory board

F. Dale Abel Members

> Robert A. Harris Takashi Kadowaki

Wannee Nitiyanant

Wayne Huey-Herng Sheu Jianping Weng


Daisuke Yabe

David D. Moore

Juliana C.N. Chan

Ikram Ismail

FLOOR PLAN



FLOOR PLAN

3F, Convention center


Meeting room (Emerald hall)

Commemoration hall for 50th anniversary of KDA (Diamond hall)

Welcome reception


50th anniversary zone

International administration office



1F, Convention center

Booth exhibition
Coffee
Luggage check
Poster exhibition



PROGRAM AT A GLANCE

1 st day (Thursday 11 October 2018)			
Room	Convention hall A, 4F	Convention hall B, 4F	Convention hall C, 4F
Session Time	Clinical diabetes and therapeutics	Behavioral medicine/Education/ Clinical nutrition/Self-care	Diabetes Complications & Comorbidity
16:00~17:00		Diabetes together with NAFLD	S1 Diabetes, retina, vision
17:00~17:30			, , , , , , , , , , , , , , , , , , , ,
17:30~18:00		Satellite symposium 1	Satellite symposium 2
18:00 ~ Welcome reception (Lobby 3F)			
2 nd day (Friday 12 October 2018)			
08:00~09:00	Breakfast symposium 1 (Grand ballroom A)	Breakfast symposium 2 (Grand ballroom C)	
09:00~10:40	S2 Comorbidities of T2DM	S3 Lifestyle factors	S4 Diabetes, cognition
10:40~11:00	Coffee break (Lobby 3F, 4F)		
11:00~11:10	Opening address		
11:10~11:50	* Plenary lecture 1		
11:50~12:10	Break (Poster viewing)		
12:10~13:20	Luncheon symposium 1	Luncheon symposium 2	Luncheon symposium 3
13:20~15:00	S7 Benefit and harm of	S8 Patient-centered education	S9 Diabetes, epigenetics,
15:00~15:20	anti-diabetic agent	∩ EN→KO	complications
15:20~16:00	Satellite symposium 3	Satellite symposium 4	Satellite symposium 5
16:00~16:20			
16:20~18:00	KDA, 50 th anniversary, perspectives OKO—EN		Diabetes in Asia
18:00 ~	Dinner (Grand ballroom, 2F, Hotel)		

Emerald Hall A, 3F	Emerald Hall B, 3F	Meeting room, Hotel, 2F	Room
Insulin action/Obesity/Integrated physiology	Islet biology & insulin secretion/ Epidemiology	Oral presentation	Session Time
		OP1[Crane] OP2 [Swan] OP3 [White heron]	16:00~17:00
			17:00~17:30
			17:30~18:00
	Welcome reception (Lobby 3F)		18:00~
			08:00~09:00
S5 Obesity, browning and whitening	S6 Genetics, epigenetics, type 2 diabetes	Clinical trials in Korea [Flamingo]	09:00~10:40
	Coffee break (Lobby 3F, 4F)		10:40~11:00
			11:00~11:10
			11:10~11:50
	Break (Poster viewing)		11:50~12:10
Luncheon symposium 4			12:10~13:20
C10 NATI D and dishates	S11 Beta cell identity		13:20~15:00
S10 NAFLD and diabetes	Diabetes and metabolism journal session	OP4 [Crane] / OP5 [Swan]	15:00~15:20
		OP6 [White heron] / OP7 [Flamingo]	15:20~16:00
	Coffee break (Lobby 3F, 4F)		16:00~16:20
S12 Skeletal muscle energy metabolism			16:20~18:00
	Dinner (Grand ballroom, 2F, Hotel)		18:00~

PROGRAM AT A GLANCE

	3 rd day (Sa	aturday 13 October 2018)	
08:00~09:00	Breakfast symposium 3 (Grand ballroom A)	Breakfast symposium 4 (Grand ballroom C)	
09:00~11:00	S13 Diabetes and gut	S14 Sweeteners and fructose ○ EN→KO	S15 Diabetes, microvascular, complications
11:00~11:20	Coffee break (Lobby 3F, 4F)		
11:20~12:00	* Plenary lecture 2		
12:00~12:20	Break (Poster viewing)		
12:20~13:30	Luncheon symposium 5	Luncheon symposium 6	Luncheon symposium 7
13:30~14:30			
14:30~16:30	S17 Hypoglycemia		S18 Diabetic neuropathy
16:30 ~			Closing ceremony

			08:00~09:00
S16 Leptin action, energy balance, hypothalamus	Diabetes guideline	Diabetes drug, approval, insurance [Flamingo]	09:00~11:00
Coffee break (Lobby 3F, 4F)		11:00~11:20	
			11:20~12:00
Break (Poster viewing)		12:00~12:20	
			12:20~13:30
		OP8 [Crane] / OP9 [Swan] OP10 [White heron] / OP11 [Flamingo]	13:30~14:30
			14:30~16:30
			16:30 ~

16:00~17:30, Convention hall B

RG1 Diabetes together with NAFLD

Translational understanding for NAFLD in T2DM Chairman: Dae Ho Lee, Chul-Hee Kim

- RG1-1 Growth differentiation factor 15: an important immunometabolic regulator in hepatic inflammation and insulin resistance

 Hyon-Seung Yi (Chungnam National University, Korea)
- RG1-2 New therapeutic approaches for non-alcoholic steatohepatitis: autophagy and inflammasome

 Yong-ho Lee (Yonsei University, Korea)
- RG1-3 Nutrient sensing nuclear receptors control liver energy balance

David D. Moore (Baylor University, USA)

RG1-4 Organokines and non-alcoholic fatty liver disease (NAFLD)

Kyung Mook Choi (Korea University, Korea)

Organizer: KDA research group on fatty liver disease

This session entitled with 'diabetes together with NAFLD' is translational session and designed to provide a place for clinicians and basic researchers to understand the novel pathophysiologies and potential therapeutic areas for NAFLD in patient with diabetes. In this session, a variety of therapeutic targets based on the novel NAFLD pathophysiologies especially in T2DM patients, including autophagy, inflammasone, FXR/PPARa, organokines and important immunologic regulators, will be presented and discussed. This session will be the first step toward better understanding the importance of NAFLD in T2DM.

16:00~17:30, Convention hall C

S1 Diabetes, retina, vision

Diabetic retinopathy: out of sight, out of mind Chairman: Ho Sang Shon, Kyu Jeung Ahn

- S1-1 A new approach to retinal vascular diseases Dong Ho Park (Kyungpook National University, Korea)
- S1-2 **Novel target for diabetic chorioretinopathy**Jun Yeop Lee (Yeungnam University, Korea)
- S1-3 Sustained inflammation and fibrosis in pericyte-deficient retina

Akiyoshi Uemura (Nagoya City University, Japan)

Panel discussion Nan Hee Kim (Korea University, Korea), Jaetaek Kim (Chung-Ang University, Korea)

Organizers: Nan Hee Kim, Jaetaek Kim

This session entitled with 'diabetes, retina, vision' is *translational session* and designed to provide a place for *clinicians and basic researchers* to understand the novel mechanisms and potential therapeutic areas for diabetic retinopathy. Clinical ophthalmology and basic research have complimentarily accumulated invaluable information of drug discovery for diabetic retinopathy. In this session, invited speakers will present the utility of experimental mouse retinal models, and the perspectives on new drugs targeting vascular signals.

16:00~17:00, Crane, Hotel 2F

Chairman: Chang Beom Lee

Oral presentation 1

Behavior, nutrition, education & exercise

16:00~17:00, Swan, Hotel 2F

Chairman: Kang Seo Park

Oral presentation 2

Clinical diabetes I

16:00~17:00, White heron, Hotel 2F

Chairman: Seok Won Park

Oral presentation 3

Insulin secretion & Integrated physiology / obesity I

09:00~10:40, Convention hall A

S2 Comorbidities of T2DM

Update of multifactorial management for comorbidities of T2DM

Chairman: Kun Ho Yoon, Linong Ji

S2-1 Preventing serious health consequences of type 2 diabetes - the evidence

Hertzel C. Gerstein (McMaster University, Canada)

S2-2 Current recommendations for the treatment of dyslipidemia in T2DM

Sung Hee Choi (Seoul National University, Korea)

S2-3 **Hypertension update: current guidelines**

Joong-Wha Chung (Chosun University, Korea)

S2-4 Anti-platelet therapy

Young-Hoon Jeong (Gyeongsang National University, Korea)

Organizers: Sung Hee Choi, Sang Soo Kim

This session entitled with 'comorbidities of T2DM' is *clinical session* and designed to provide a place for *clinicians* to discuss the evidences of preventing and managing cardiovascular comorbidities in patients with T2DM. In this session, the multifactorial strategy for management of comorbidities in patients of T2DM, including dyslipidemia, hypertension and increased platelet aggregation, will be presented and discussed. This session will give a comprehensive and effective multifactorial approach ensuring maximum benefit for patients with T2DM.

09:00~10:40, Convention hall B

Lifestyle factors OEN-KO
Lifestyle factors and the risk of type 2 diabetes Chairman: In Joo Kim, John Chiang

S3-1 Dietary priorities for type 2 diabetes Nita G Forouhi (University of Cambridge, UK)

S3-2 Dietary intake and the risk of type 2 diabetes in Korea

Yoon Ju Song (The Catholic University of Korea, Korea)

S3-3 Cardioresiratory fitness and the risk of type 2 diabetes Sae Young Jae (University of Seoul, Korea)

S3-4 **EDCs and the risk of type 2 diabetes** Duk Hee Lee (Kyungpook National University, Korea)

Organizers: Committee of education, Hae Jin Kim

Lifestyle management is a fundamental aspect of diabetes care. This session is *clinical* session and designed to provide a place for diabetes educators to understand the association between **lifestyle factors and the risk of type 2 diabetes**. In this session, four speakers with a volume of experience in the field will deliver a lecture, focused on the effects of nutrtion, exercise, and EDCs (endocrine disrupting chemical) on the risk of type 2 diabetes. This session will give a better understanding for the importance of lifestyle factors in type 2 diabetes. Please join us for this session and enjoy the exciting discussion.

09:00~10:40, Convention hall C

S4 Diabetes, cognition

Beyond old paradigm: diabetes-associated cognitive dysfunction

Chairman: Jae Myung Yu, Adam R. Wende

S4-1 Connections between diabetes and cognitive dysfunction

Seung-Hwan Lee (The Catholic University of Korea, Korea)

S4-2 Neuroprotective effect of inulin signaling defect

Martin Holzenberger (INSERM and Sorbonne University, France)

S4-3 Neuroprotective effect of insulin signaling

Sun Ah Park (Ajou University, Korea)

Panel discussion Nan Hee Kim (Korea University, Korea), Jaetaek Kim (Chung-Ang University, Korea)

Organizers: Nan Hee Kim, Jaetaek Kim

This session entitled with 'diabetes, cognition' is translational session and designed to provide a place for clinicians and basic researchers to understand the novel mechanisms and potential therapeutic areas for diabetic cognitive dysfunction. Although microvascular and macrovascular complications of diabetes are well recognized, there is a lack of awareness regarding other complications such as cognitive dysfunction, and dementia. In this session, invited speakers will explain the interconnecting link between diabetes and cognitive dysfunction. This session will be the important step toward better understanding the cognitive dysfunction in diabetes.

09:00~10:40, Emerald hall A

S5 Obesity, browning and whitening Adipocyte lipotoxicity "friend or foe?"

Chairman: Ki-Up Lee, Barbara B. Kahn

S5-1 The dark side of PGC-1: from dark skin to dark fat

Zoltan P. Arany (University of Pennsylvania, USA)

- S5-2 Crosstalk between adipokines and hepatokines in the maintenance of metabolic homeostasis and cardiovascular health

 Aimin Xu (University of Hong Kong, Hong Kong)
- S5-3 Mitophagy is necessary for the maintenance of brown fat function.

Eun Hee Koh (University of Ulsan, Korea)

S5-4 Novel roles of lipid droplet binding proteins in fat tissue

Jae Bum Kim (Seoul National University, Korea)

Organizer: Eun Hee Koh

This session entitled with 'obesity, browning and whitening' is basic session. Metabolically active brown adipose tissue playing an important role in metabolic control and body weight regulation exists in humans. Recently, many studies demonstrate that subcutaneous white adipose tissue can metabolize stored energy in brown-like ("beige" or "browing") adipocytes to contribute to overall energy expenditure. In this session, a new molecular mechanism and pathophysiology of white-to-brown adipocytes in the obesity development, will be presented and discussed. This session will present a new therapeutic strategy for managing obesity and obesity-related metabolic diseases.

09:00~10:40, Emerald hall B

S6 Genetics, epigenetics, type 2 diabetes

Genetics/epigenetics in T2DM

S6-1 Genetic and epigenetic research on type 2 diabetes in Koreans

Soo Heon Kwak (Seoul National University, Korea)

S6-2 Understanding the pathogenesis of type 2 diabetes, one variant at a time

Mark I. McCarthy (University of Oxford, UK)

Chairman: Hak Chul Jang, Min Ho Shong

S6-3 Genetics and diabetic complications

Juliana CN Chan (The Chinese University of Hong Kong, Hong Kong)

S6-4 Identification of obesity genes and their functional validation

Yoon Shin Cho (Hallym University, Korea)

Organizers: Hye Jin Lee, Tae Seo Sohn

This session entitled with 'genetics, epigenetics, type 2 diabetes' is *translational session* and designed to provide a place for *clinicians* and *basic researchers* to understand genetics and epigenetics in type 2 diabetes. In this session, a recent progress in genetics and epigenetic research on type 2 diabetes and genetics and diabetic complications will be presented and discussed. This session will contribute toward precision medicine and be first step toward better understanding the complex mix of genetic, epigenetic, and environmental influences in type 2 diabetes.

09:00~10:40, Flamingo

RG2 Clinical trials in Korea (Korean)

Noteworthy clinical trials in Korean type 2 diabetes

Chairman: Moon-Suk Nam, Hyuk-Sang Kwon

RG2-1 Efficacy and safety of lixisenatide in Korean type 2 diabetic patients with basal insulin failure

Nan Hee Kim (Korea University, Korea)

RG2-2 Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Korean patients

with type 2 diabetes

Min Kyong Moon (Seoul National University, Korea)

RG2-3 Liraglutide provides similar glycaemic control as glimepiride and reduces body weight and hypoglycaemia events in Asian population with type 2 diabetes:

the Korean subgroup analysis

Sang Youl Rhee (Kyung Hee University, Korea)

RG2-4 Efficacy and safety of dapagliflozin in Korean patients with type 2 diabetes

Kyu Yeon Hur (Sungkyunkwan University, Korea)

RG2-5 **Teneligliptin clinical trials in Korea**Eun Seok Kang (Yonsei University, Korea)

RG2-6 Efficacy and safety of evogliptin in Korean patients with type 2 diabetes

Jung Hyun Noh (Inje University, Korea)

RG2-7 **Summary** Seung-Hyun Ko (The Catholic University of Korea, Korea)

Organizer: Committee of clinical practice guideline

This session entitled with 'clinical trials in Korea' is *clinical* session and designed to provide a place for *clinicians* to understand the noteworthy clinical trials in Korean patients with type 2 diabetes. In this session, results of clinical trials of Korean patients with type 2 diabetes, including degludec, liraglutide, dapagliflozin, evogliptin, and teneligliptin, will be presented and discussed. By understanding the results of clinical studies conducted in Koreans, we will help to understand the characteristics and treatment directions of diabetes in Koreans.

Chairman: Kyong Soo Park

11:10~11:50, Convention hall A, B, C

Plenary lecture 1 OEN-KO

PL1 De novo lipogenesis in adipocytes and the production of lipids with beneficial metabolic effects

Barbara B. Kahn (Harvard University, USA)

Dr. Barbara B. Kahn is Professor of Medicine, Harvard Medical School and vice chair for research strategy, department of medicine, Beth Israel Deaconess Medical Center. Dr. Kahn's research has delved into understanding the critical role of the adipocyte as an endocrine organ and led to the discovery of novel adipocyte-secreted molecules such as RBP4 that is linked to insulin resistance and to the risk for T2DM and cardiovascular disease in humans. She is best known for establishing a critical role for the AMP-activated protein kinase pathway in leptin action in both the hypothalamus and peripheral tissues. She received 2016 Banting Award from the American Diabetes Association and was elected to the US National Academy of Sciences in 2017. In ICDM 2018, She will deliver a lecture entitled "Novel class of signaling lipids with beneficial metabolic effects" based on her scientific journey.

13:20~15:20, Convention hall A

S7 Benefit and harm of anti-diabetic agent

Multifaced beneficial and harmful effects of anti-diabetic agent

Chairman: Moon-Kyu Lee, Robert A Ritzel

- S7-1 **TZD's benefits and side effects and about the new PPAR enhancing agents to avoid those side effects** *Toshimasa Yamauchi (University of Tokyo, Japan)*
- S7-2 Benefit and harm of anti-diabetic agent: DPP4 inhibitors

S7-3 GLP-1 RA more benefits than harm

S7-4 SGLT-2 inhibitors

Mark E Cooper (Monash University, Australia)
Paolo Pozzilli (University Campus Bio-Medico, Italy)

Ofri Mosenzon (Hadassah Hebrew University, Israel)

Organizers: Sang Yong Kim, Cheol-Young Park

This session entitled with 'benefit and harm of anti-diabetic agents' is clinical session and designed to provide a place for clinicians and basic researchers to elucidate the mechanism, efficacy and side effect of anti-diabetic agents. Despite the pharmacotherapy is essential component for treatment of diabetes, It is like a double-edged sword when used without knowing it exactly. In this session, four lecturer give a talk about the various data from pharmacokinetics to clinical benefit and harm of each class of anti-diabetic agents. Through this session, we hope that many clinicians will have the opportunity to learn more about the knowledge and appropriate use of anti-diabetic agents.

13:20~15:20, Convention hall B

S8 Patient-centered education OEN-KO

Integrated diabetes management via patient-centered education and new technology

Chairman: Kwan Woo Lee, Nita G Forouhi

S8-1 Achieving better glycemic control: unmet needs and main barriers

Jeong Rim Lee (Asan Medical Center, Korea)

S8-2 A novel approach to improving adherence and patient outcomes in T2DM

Hye Ryoung Yun (Chonbuk National University Hospital, Korea)

S8-3 Using a digital platform for connecting patients and healthcare professionals

Juliana CN Chan (The Chinese University of Hong Kong, Hong Kong)

S8-4 Innovations in insulin delivery, automation and closed loop therapy

Scott W. Lee (Medtronic Diabetes, USA)

Organizers: Korean Association Diabetes Nurse Educators, Hae Jin Kim

This session entitled with 'patient-centered education' is *clinical session* and designed to serve challengeable issues for *diabetes educators and clinicians* to understand integrated diabetes management via new technology. In this session, the unmet needs and main barriers for achieving better glycemic control, a novel approach to improving adherence, patient outcomes using a digital platform and the new insulin delivery system in patient with diabetes will be presented and discussed. This session will be showing the various strategies to health care professionals to educate the patients for the good diabetes management.

13:20~15:20, Convention hall C

S9 Diabetes, epigenetics, complications

Epigenetics: cutting-edge research - application to diabetic complications

Chairman: Byung-Joon Kim, Melanie Cree-Green

S9-1 Lipid and ROS-induced mechanisms for diabetic cardiomyopathy

E. Dale Abel (University of Iowa, USA)

S9-2 Study of noncoding RNAs in vascular smooth muscle cells

Young-Kook Kim (Chonnam National University, Korea)

S9-3 Urinary proteome analysis for biomarker discovery to predict renal function decline of diabetic nephropathy

Kyung Gon Kim (University of Ulsan, Korea)

Panel discussion

Sang Soo Kim (Pusan National University, Korea) Kyu-Sang Park (Yonsei University, Korea) Chan Bae Park (Ajou University, Korea)

Organizers: Nan Hee Kim, Jae Taek Kim

This session entitled with 'diabetes, epigenetics, complications' is *translational session* and designed to provide a place for *clinicians and basic researchers* to understand epigenetics of diabetic complications. Epigenetic modifications are one of the most important means for the temporal and spatial control of gene activity. Many studies indicate that specific epigenetic events contribute to programming for the development and progression of diabetic complications. The invited speakers will present their recent works successfully using these strategies to identify novel mechanisms influencing diabetic complications..

13:20~15:20, Emerald hall A

S10 NAFLD and diabetes

Organ crosstalk in obesity and NAFLD

Chairman: Hong Kyu Lee, Sung Hee Ihm

- S10-1 Innate immunity and NAFLD
- Hongliang Li (Wuhan University, China)
- S10-2 Bile acid signaling in the gut: novel therapeutic strategy for type 1 and 2 diabetes

Sung Soon Fang (Yonsei University, Korea)

- S10-3 Gα13 ablation reprograms myofibers to oxidative phenotype and enhances whole-body metabolism

 Sana Geon Kim (Seoul National)
 - Sang Geon Kim (Seoul National University, Korea)
- S10-4 Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice

David D. Moore (Baylor University, USA)

Organizers: Yong Ho Lee, Keun-Gyu Park

This session entitled with 'NAFLD and diabetes' is basic and translational session and designed to provide a place for basic researchers and clinicians to understand the novel pathophysiology and potential therapeutic targets for obesity and NAFLD. In this session, various mechanisms including gut-liver or muscle-liver axis, immunology and hepatic FXR/SHP pathways will be presented and discussed by outstanding international speakers. It will also cover the repertoire of inter-organ communications and aging that have an influence on metabolic diseases.

13:20~15:00, Emerald hall B

S11 Beta cell identity

Beta cell heterogeneity and dedifferentiation Chairman: Kwang-Won Kim, Yutaka Seino

S11-1 Regulating beta cell identity

- *Lori Sussel (University of Colorado, USA)*
- S11-2 Deciphering pancreatic islet β-cell and α-cell maturation pathways and characteristic features at the single-cell level

 Cheng-Ran Xu (Peking University, China)
- S11-3 Epigenetic control of mature β-cell identity by PRMT1 dependent H4R3me2a

Hail Kim (KAIST, Korea)

S11-4 Non-islet cell deserves more attention; how non-islet cells help and support beta cells

Shin Ae Kang (Yonsei University, Korea)

Organizers: Shin Ae Kang, Hail Kim

This islet biology session is entitled 'beta cell identity'. Beta cell death has been thought as the major mechanism for beta cell failure. However, recent studies indicate that beta cell dedifferentiation can result in the loss of functional beta cell mass and thereby can alter glucose homeostasis. Beta cell dedifferentiation begins with the loss of mature beta cell identity. In this session, speakers will discuss how does beta cell lose its mature identity and dedifferentiation progress. This session will broaden out understanding about the mature beta cell identity.

15:00~16:00, Emerald hall B

SP1 Diabetes and metabolism journal session

Diabetes-DMJ joint symposium

Chairman: Kyu Chang Won, K. Sreekumaran Nair

- SP1-1 **Reflections of a previous editor of diabetes** K. Si
- K. Sreekumaran Nair (Mayo Clinic, USA)

SP1-2 Overview of DMJ

- Tae Seo Sohn (The Catholic University of Korea, Korea)
- SP1-3 Generation of insulin-expressing cells in mouse small intestine by Pdx1, MafA, and BETA2/NeuroD

 Kun Ho Yoon (The Catholic University of Korea, Korea)
- SP1-4 Determinants of long-term durable glycemic control in new-onset type 2 diabetes

Nam Hoon Kim (Korea University, Korea)

SP1-5 Satisfaction survey on information technology-based glucose monitoring system targeting diabetes mellitus in private local clinics in Korea

Jae Hyoung Cho (The Catholic University of Korea, Korea)

Organizer: Committee of publication

This session entitled with 'Diabetes-DMJ joint symposium' is translational session and designed to provide a place for clinicians and basic researchers. 'Diabetes' and 'DMJ' publish original research relevant to diabetes and are indexed in SCI(E). 2017 impact factor of DMJ is 3.710. The Committee of Publication of KDA has selected the best articles among papers published in DMJ in 2017. In this session, reflection on 'Diabetes' as an editor-inchief and overview of DMJ will be presented. And the authors of the selected articles will share results of their outstanding researches.

15:00~16:00, Crane, Hotel 2F

Chairman: Sung-Hoon Kim

Oral presentation 4

Epidemiology / genetics

15:00~16:00, Swan, Hotel 2F

Chairman: Ji Hyun Lee

Oral presentation 5

Clinical diabetes II

15:00~16:00, White heron, Hotel 2F

Chairman: Sang Ah Chang

Oral presentation 6

Insulin secretion / Integrated physiology / obesity II

15:00~16:00, Flamingo, Hotel 2F

Chairman: Choon Hee Chung

Oral presentation 7

Macrovascular complications

16:20~18:00, Convention hall A, B

SP2 KDA, 50th anniversary, perspectives (Korean) NO-EN KDA's perspectives for ever-changing diabetes in Korea

Chairman: In-Kyu Lee

- SP2-1 **Our 50-year challenge for the future**Hyung Joon Yoo (CM Hospital, Korea)
- SP2-2 Diabetes epidemiology in Korean and Asian population Nam Han Cho (Ajou University, Korea)
- SP2-3 **Pathogenesis of type 2 diabetes in Korean** Kyong Soo Park (Seoul National University, Korea)
- SP2-4 **Beyond KDA, toward world** Kyung Soo Ko (Inje University, Korea)

Organizer: Committee for KDA 50th anniversary

In honor of the KDA marking 50 years of research and collaboration for diabetes since 1968, KDA will be hosting a special 50th anniversary symposium, "perspectives for ever-changing diabetes in Korea" on Oct 12, 2018. In this symposium, changes of epidemiology and pathophysiology in Korean patients with diabetes will be reviewed. This symposium is open to all and will shed light on the past, current and future challenges facing KDA and the exciting activities of KDA.

16:20~18:00, Convention hall C

RG3 Diabetes in Asia

Sharing real experience of diabetes epidemiologic research

Chairman: Doo-Man Kim, Takashi Kadowaki

RG3-1 Effect of an intensified multifactorial intervention on cardiovascular and renal outcomes and mortality in type 2 diabetes (J-DOIT3)

Takashi Kadowaki (University of Tokyo, Japan)

RG3-2 Developmental origins of T2DM: a perspective from China

Ronald C.W. Ma (Chinese University of Hong Kong, Hong Kong)

RG3-3 Diabetes epidemic and diabetes care system in Korea

Dae Jung Kim (Ajou University, Korea)

Panel discussion

Touch Khun (Preah Kossamak Hospital, Cambodia)
Altaisaikhan Khasag (Mongolian National University, Mongolia)
Ikram Shah Ismail (University of Malaya, Malaysia)
Wannee Nitiyanant (Mahidol University, Thailand)
Alimov Anvar Valievich (Ministry of Health, Uzbekistan)

Organizer: Committee of international liaison

This session entitled with 'diabetes in Asia' is a *clinical session* and designed to make an international occasion for gathering of Asian experts (*clinicians and epidemiologic researchers*) in diabetes care. The representatives participating speakers and panels from more than 10 countries from all over the Asia will present and discuss their experience in diabetes prevention, perspectives and their healthcare system. The ultimate goal of this session resides in continuous collaboration and friendship among the Asian countries and diabetes societies in the prevention and management of diabetes in Asia in the future.

16:20~18:00, Emerald hall A

- Steletal muscle energy metabolism
 Skeletal muscle energy metabolism
- S12-1 Regulation of skeletal muscle mitochondrial biogenesis and functions

K . Sreekumaran Nair (Mayo Clinic, USA)

Chairman: Joong Yeol Park, Zoltan P. Arany

S12-2 Effect of hypothalamic leptin resistance on energy metabolism in skeletal muscle

Dae-Kyu Song (Keimyung University, Korea)

- S12-3 **Skeletal muscle as a therapeutic target for diabetes** Cheol Soo Choi (Gachon University, Korea)
- S12-4 Advances in understanding skeletal muscle insulin sensitivity across the lifespan

Melanie Cree-Green (University of Colorado, USA)

Organizers: Hye Soon Kim, Dae Ho Lee

This translational session entitled 'skeletal muscle energy metabolism' was organized to provide pathophysiologic and therapeutic implications of diabetes and insulin resistant conditions to both physicians and basic researchers. Focusing on skeletal muscle among insulin-sensitive tissues, four excellent speakers will present and discuss about exercise type-dependent physiology, muscle thermogenesis and energy metabolism, glucose metabolism based on human clamp study, and skeletal muscle hypertrophy as a therapeutic strategy. This session will be very helpful for in-depth understating of skeletal muscle energy metabolism in both physiologic and therapeutic aspects.

09:00~11:00, Convention hall A

S13 Diabetes and gut

Diabetes and gut

Chairman: Yeon Ah Sung, Philipp E. Scherer

- S13-1 Diabetes and gut, overview of the interplay Myung-Shik Lee (Yonsei University, Korea)
- 513-2 The role of incretin in the glucose homeostasis Young Min Cho (Seoul National University, Korea)
- S13-3 Activation of bile acid receptor signaling shapes the gut microbiota to improve diabetes and fatty liver disease John Chiang (Northeast Ohio Medical University, USA)
- S13-4 Metabolic surgery of the gut for diabetes

Soo Min Ahn (Hallym University, Korea)

Organizers: In-Kyung Jeong, Jung Hyun Noh

This session entitled with 'diabetes and gut' is translational session and organized to provide deep insight for clinicians and basic researchers to understand the important factors of the gastrointestinal tract for glucose regulation in humans. This session consists of overview of the role of gut in glucose homeostasis, special lectures on incretin hormone, bile acid metabolism, gut microbiota, and the metabolic effect of bariatric surgery. This session will be very helpful for better understanding the underlying pathophysiology and planning the therapeutic strategies for T2DM.

09:00~11:00, Convention hall B

S14 Sweeteners and fructose OEN-KO

Sweeteners and fructose in diabetes: good or bad?

Chairman: Dong Sun Kim, Ofri Mosenzon

- S14-1 Controversies about non-nutritive sweeteners consumption and type 2 diabetes: current state of the science Su Jin Song (Hannam University, Korea)
- S14-2 Safety and metabolic effects of low-calorie sweeteners Sun Min Park (Hoseo University, Korea)
- S14-3 Effect of fruit juice intake on glycemic control and insulin sensitivity in obesity
 and diabetes

 Yun Sook Lim (Kyunghee University, Korea)
- S14-4 **Fructose in diabetes: friend or foe?**Chong Hwa Kim (Sejong general hospital, Korea)

Organizers: Committee of food and nutrition, Hae Jin Kim

This session entitled with 'sweeteners and fructose in diabetes: good or bad?' is a *clinical session* designed to provide a place for *dietitians*, *clinicians*, *and other diabetes educators*. In this session, controversies about sweeteners and health, current guidelines for sweeteners consumption, and safety and metabolic effects of low-calorie sweeteners will be presented and discussed. Secondly, the effects of fructose on metabolism, and the benefit and risk of consumption of foods that contain fructose including fruit juice will be discussed. This session will suggest the right ways to consumption of sweeteners and high-fructose foods in diabetic patients.

09:00~11:00, Convention hall C

S15 Diabetes, microvascular, complications

Three tough questions that are difficult to answer. Chairman: Yong-Wook Cho, E. Dale Abel

- S15-1 Acute kidney injury: mechanism of AKI sensitivity in diabetic nephropathy
 - Sang Heon Song (Pusan National University, Korea)
- S15-2 Long journey to overcome diabetic kidney disease. Where are we?

Mark E Cooper (Monash University, Australia)

S15-3 Therapeutic application of in vivo genome editing for diabetic retinopathy

Jeong Hun Kim (Seoul National University, Korea)

Organizers: Nan Hee Kim, Jaetaek Kim

This session entitled with 'diabetes, microvascular, complications' is translational session and designed to provide a place for clinicians and basic researchers to understand the important pathophysiologic mechanisms of diabetic microvascular complications. Although there has been a big improvement in the treatment and prognosis of diabetic kidney disease (DKD), there remains an unmet need for innovative treatment. The invited speakers will present the overview of recent preclinical and clinical studies of DKD and the connections between diabetic vascular complications, which demonstrate new insights to outline directions with respect to novel therapies.

09:00~11:00, Emerald hall A

S16 Leptin action, energy balance, hypothalamus

Novel players in the central regulation of metabolism Chairman: Min Seon Kim, Lori Sussel

S16-1 Activation of AMPK in CRH neurons in the paraventricular hypothalamus induces food preference for carbohydrate over fat

Yasuhiko Minokoshi (National Institute for Physiological Sciences, Japan)

S16-2 FoxO1 regulates the behavioral manifestation of leptin in dopaminergic neurons

Ki Woo Kim (Yonsei University, Korea)

S16-3 Role of hypothalamic tanycytes in metabolic homeostasis

Vincent Prevot (University of Lille, France)

S16-4 Control of energy balance by Rho-kinase

Young-Bum Kim (Harvard University, USA)

Organizer: Young-Bum Kim

This session entitled with "leptin action, energy balance, hypothalamus" is basic session and designed to provide new knowledge in the field of metabolic physiology for clinical and basic investigators. This session will address the latest advances that are linked to the functions of hypothalamus in regulating energy balance and feeding behavior. This session will also focus on the role of intracellular signaling mediators in controlling leptin action, with a particular emphasis on the etiopathogenesis of leptin resistance in obesity. This session will have broad impact on the understanding of the basic biology of brain function in obesity-related metabolic disorders.

09:00~11:00, Emerald Hall B

RG4 Diabetes guideline

Diabetes guidelines in perspectives of Asian diabetes phenotype

Chairman: Hyun Shik Son, Young Sik Choi

RG4-1 Optimal BP control target in Asian diabetes; the lower, the better?

Mee Kyoung Kim (The Catholic University of Korea, Korea)

RG4-2 LDL-C management in Asian diabetes; moderate vs. high intensity statin

- a lesson from EMPATHY study

Hiroshi Itoh (Keio University, Japan)

RG4-3 Glycemic control target in Asian diabetes: HbA1c < 6.5% vs. < 7%?

Dae Jung Kim (Ajou University, Korea)

Panel discussion

Sang Yong Kim (Chosun University, Korea) Bo Yeon Kim (Soonchunhyang University, Korea) Eun-Jung Rhee (Sungkyunkwan University, Korea)

Organizer: Committee of clinical practice guideline

This session entitled with 'diabetes guidelines' is *clinical session* and designed to provide a place for *clinicians* to understand the cardiovascular risk factor targets in Asian patient with diabetes. In this session, optimal blood pressure goals, LDL cholesterol management (moderate vs. high intensity statin) and glycemic control goals (HbA1c < 6.5% vs. < 7%) in Asian diabetes will be presented and discussed. This session will provide updated cardiovascular risk factor targets in diabetes.

09:00~11:00, Flamingo

RG5 Diabetes drug, approval, insurance (Korean)

Solutions to differences in diabetes drug aproval and insurance standards

Chairman: Tae Sun Park, Seok O Park

RG5-1 Principles of setting up drug insurance standards, focusing on diabetes drugs

Mijeong Koo (Ministry of Health and Welfare, Korea)

RG5-2 Proposal for the principle of insurance application of anti-diabetic drugs

Woo Je Lee (University of Ulsan, Korea)

Panel discussion

Gi Hyeon Seo (HIRA, Korea) Kyeong Hye Park (National Health Insurance Ilsan Hospital, Korea) Ministry of Food and Drug Safety

Organizer: Committee of the health insurance and legislation

Diabetes drugs, which have annual sales of KRW 1 trillion, are different in their efficacy and indications. However, the range of coverage varies even for each series and each individual component, so the conflicts and burdens of prescribing physicians and patients are continuing. Based on the evidence and guidelines, we will discuss how to apply the principles of insurance standard setting to the development of effectiveness and safety verification and policy considerations for diabetics in Korea.

SCIENTIFIC PROGRAM

11:20~12:00, Convention hall A, B, C

Plenary lecture 2 OEN-KO

Chairman: In-Kyu Lee

The adipocyte: a key target for diabetes research

Philipp E. Scherer (UT Southwestern Medical Center, USA)

Prof. Philipp Scherer is the director of the Touchstone Diabetes Center at the University of Texas Southwestern Medical Center. Prof. Scherer's research has delved into the integrated physiology of the adipocyte and the impact on whole body energy homeostasis, inflammation and cancer. He is best known for the identification of adipocyte-derived factors (adipokines). And he cloned adiponectin and has implicated the downstream signaling of adiponectin in the regulation of carbohydrate and lipid metabolism as well as the roles of adiponectin in cancer cell growth and survival. He has received numerous awards, including the 2015 Banting Award for Outstanding Scientific Achievement and 2012 J. Dennis McGarry Award by the American Diabetes Association. In ICDM 2018, he will deliver a lecture entitled "The adipocyte: a key target for diabetes research" based on his scientific journey.

13:30~14:30, Crane, Hotel 2F

Chairman: Jung Guk Kim

Oral presentation 8

Metabolic syndrome & prediabetes

13:30~14:30, Swan, Hotel 2F

Chairman: Dong-Jun Kim

Oral presentation 9

Therapeutics of diabetes

13:30~14:30, White heron, Hotel 2F

Chairman: Sung Dae Moon

Oral presentation 10

Insulin secretion / Integrated physiology / obesity III

13:30~14:30, Flamingo, Hotel 2F

Chairman: Tae Keun Oh

Oral presentation 11

Microvascular complications

SCIENTIFIC PROGRAM

14:30~16:30, Convention hall A

S17 Hypoglycemia

Clinical re-establishment of hypoglycemia

Chairman: Jeong Taek Woo, Robert A. Harris

- S17-1 **Hypoglycemia and CVD outcome** Seung-Hyun Ko (The Catholic University of Korea, Korea)
- S17-2 Control of glycemic variability for reducing hypoglycemia

Jaehyeon Kim (Sungkyunkwan University, Korea)

S17-3 Treatment strategy for avoiding hypoglycemia

Robert A Ritzel (Munich Schwabing Hospital, Germany)

S17-4 Overcome of hypoglycemia unawareness

Hyun Min Kim (Chung-Ang University, Korea)

Organizers: In-Kyung Jeong, Jung Hyun Noh

This session entitled with 'clinical re-establishment of hypoglycemia' is a clinical session designed to provide a place for clinicians and diabetes educators. In this session, an update of adverse clinical outcomes of hypoglycemia will be presented, and a variety of strategies for preventing hypoglycemia including control of glycemic variability, new drugs with less hypoglycemia and way to overcome hypoglycemia unawareness will be introduced and discussed. This session will provide an updated treatment strategy to avoid hypoglycemia for your diabetic patients.

14:30~16:30, Convention hall C

S18 Diabetic neuropathy

All that diabetic neuropathy

Chairman: Kyung Wan Min, Yu-Bae Ahn

- S18-1 Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management Vincenza Spallone (University of Rome Tor Vergata, Italy)
- S18-2 Pathogenesis of diabetic neuropathy from the point of view of schwann cell abnormalities

 Koichi Kato (Aichi Gakuin University, Japan)
- S18-3 New hope in management of diabetic peripheral neuropathy

Tae Sun Park (Chonbuk National University, Korea)

Panel discussion

Eun Young Lee (The Catholic University of Korea, Korea) Jae Seung Yun (The Catholic University of Korea, Korea) Chong Hwa Kim (Sejong general hospital, Korea)

Organizer: Chong Hwa Kim

This session entitled with 'diabetic neuropathy' is translational session and designed to provide a place for clinicians and basic researchers to understand the novel pathophysiologies and potential therapeutic areas for diabetic neuropathy in patient with diabetes. In this session, overview of cardiovascular autonomic neuropathy, pathogenesis of diabetic neuropathy from Schwann cell and in diabetes and a new hope of therapeutic agents in diabetic peripheral neuropathy, will be presented and discussed. This session will be provide the better understanding of pathophysiology and managemt of diabetic neuropathy included diabetic peripheral neuropathy and cardiac autonomic neuropathy.

Satellite symposia

Thursday 11 October / 17:30~18:00, Convention hall B

Chairman: Sung Koo Kang

Satellite symposium 1 (Sponsored by Yuhan)

SS1 Why should we consider SGLT-2i treatment for T2DM patients?

Sang Soo Kim (Pusan National University, Korea)

Thursday 11 October / 17:30~18:00, Convention hall C

Chairman: Min Young Chung

Satellite symposium 2 (Sponsored by Chongkundang)

What should be considered in choosing diabetic drug?: focused on synergistic effect of TZD and SGLTI

Sin Gon Kim (Korea University, Korea)

Friday 12 October / 15:20~16:00, Convention hall A

Chairman: Ho Young Son

Satellite symposium 3 (Sponsored by Takeda)

SS3 Targeting beta-cell function in T2DM: a critical factor for durability

Eun-Jung Rhee (Sungkyunkwan University, Korea)

Friday 12 October / 15:20~16:00, Convention hall B

Chairman: Sung Woo Park

Satellite symposium 4 (Sponsored by Novonordisk)

SS4 Exploring the mechanisms behind better PPG control with faster aspart

Henrik Jarlov (Novonordisk, UAE)

Friday 12 October / 15:20~16:00, Convention hall C

Chairman: Moon-Gi Choi

Satellite symposium 5 (Sponsored by Lilly)

SS5 Beyond basal insulin treatment: basal insulin combination with GLP-1RA

Paolo Pozzilli (University Campus Bio-Medico, Italy)

Breakfast symposia

Friday 12 October / 08:00~09:00, Grand Ballroom A

Chairman: Jin Woo Kim

Breakfast symposium 1 (Sponsored by MSD)

BS1 Optimized treatment for type 2 DM patients-focusing new SGLT2i, ertugliflozin

Seung-Hwan Lee (The Catholic University of Korea, Korea)

Friday 12 October / 08:00~09:00, Grand Ballroom C

Chairman: Hyoung Woo Lee

Breakfast symposium 2 (Sponsored by Novartis)

BS2 Anti-diabetic agents with high potency and low risk of hypoglycemia: reducing glucose fluctuation Hye Seung Jung (Seoul Na

Hye Seung Jung (Seoul National University, Korea)

Saturday 13 October / 08:00~09:00, Grand Ballroom A

Chairman: Young-Kil Choi

Breakfast symposium 3 (Sponsored by Sanofi Aventis)

BS3 Glargine 300 "complementing randomized controlled trials with real-world evidence"

Robert A Ritzel (Munich Schwabing Hospital, Germany)

Saturday 13 October / 08:00~09:00, Grand Ballroom C

Chairman: Yong Ki Kim

Breakfast symposium 4 (Sponsored by JW Pharmaceutical)

BS4 The additional benefit of an agliptin beyond glycemic control

Jeong Hyun Park (Inje University, Korea)

Luncheon symposia

Friday 12 October / 12:10~13:20, Convention hall A

Luncheon symposium 1 (Sponsored by Astrazeneca)

LS1 The DECLARE-TIMI 58 design and patients baseline characteristics: compression to all other CVOTs with SGLT2-INH and its implication

Ofri Mosenzon (Hadassah Hebrew University, Israel)

Friday 12 October / 12:10~13:20, Convention hall B

Luncheon symposium 2 (Sponsored by Dong-A ST)

LS2 The newest ARB, edarbi for hypertensive patients with T2DM

Jae Hyuk Lee (Myongji Hospital, Korea)

Chairman: Soon Jib Yoo

Chairman: Dong-Seop Choi

Chairman: Hyung Joon Yoo

Chairman: Kyo Il Suh

Friday 12 October / 12:10~13:20, Convention hall C

Luncheon symposium 3 (Sponsored by Ildong)

LS3 **DPP4 inhibitor: beta cell protection and albuminuria improvement effect found from evidence**Suk Chon (Kyung Hee University, Korea)

Friday 12 October / 12:10~13:20, Emerald hall A

Luncheon symposium 4 (Sponsored by Daewoong)

LS4 **Effect of dapagliflozin on vascular function in diabetes** Soo Lim (Seoul National University, Korea)

Saturday 13 October / 12:20~13:30, Convention hall A

Luncheon symposium 5 (Sponsored by LG)

LS5 Review of clinical studies comparing DPP-4 inhibitors

So Hun Kim (Inha University, Korea)

Chairman: Hyun Chul Lee

Chairman: Duk Kyu Kim

Chairman: Young Seol Kim

Saturday 13 October / 12:20~13:30, Convention hall B

Luncheon symposium 6 (Sponsored by Handok)

LS6 The multiple benefits of ipragliflozin; ideal option for Asian T2DM patients

Jun Sung Moon (Yeungnam University, Korea)

Saturday 13 October / 12:20~13:30, Convention hall C

Luncheon symposium 7 (Sponsored by Boehringer Ingelheim)

LS7 New drugs new opportunities for diabetes and its complications

Mark E Cooper (Monash University, Australia)

GENERAL INFORMATION

Operation time

Classification		Date & Time		Location	
Registration desk		October 11 (Thu) October 12 (Fri) October 13 (Sat)	15:00~17:00 08:00~17:00 08:00~14:30	Lobby, Convention Center (4F)	
Preview room		October 11 (Thu) October 12 (Fri) October 13 (Sat)	14:00~18:00 08:30~18:00 08:30~14:00	Peacock room, Hotel (2F)	
International administration office		October 12 (Fri) October 13 (Sat)	10:00~17:00 10:00~13:00	IA Office, Convention Center (3F)	
Oral presentations		October 11 (Thu) October 12 (Fri) October 13 (Sat)	16:00~17:00 15:00~16:00 13:30~14:30	Meeting room, Hotel (2F)	
Poster exhibition		October 12 (Fri) October 13 (Sat)	09:00~18:00 09:00~16:30	Lobby, Convention Center (1F, 4F)	
Exhibition		October 12 (Fri) October 13 (Sat)	09:00~17:30 09:00~16:30	Lobby, Convention Center (1F)	
	50 th Anniversary of KDA & Welcome reception	October 11 (Thu)	18:00	Lobby, Convention Center (3F)	
Social events	Opening	October 12 (Fri)	11:00~11:10	Convention hall A,B,C (4F)	
	Dinner	October 12 (Fri)	18:00	Grand ballroom, 2F, Hotel	
	Closing	October 13 (Sat)	16:30	Convention hall C (4F)	

Congress kit

Below materials are offered to registrants

Place	Registration desk	Abstract book desk			
Materials	Name tags and lanyards	A bag, an abstract book and a t-shirt			

^{*} Note: Registrants are strongly requested to wear name badge during the congress.

Travel grant

Travel grantees nominated with USD 1,000 are asked to check into the international administration office located on the lobby of convention center (3F).

WiFi

 $\label{lem:kda} KDA\ has\ arranged\ free\ WiFi\ for\ all\ delegates,\ which\ covers\ convention\ center.$

Please select the "ICDM2018" network.


- ID: ICDM2018 / Password: takeda

Lucky draw

A ticket for lucky draw will be given. Please find it in your badge, and drop it into the event box located on 4th floor. 3 winners will be selected at the closing ceremony on 13 October.

^{*} Requirements: Passport, Registration, Boarding pass

EXHIBITION



No	Exhibitor	No	Exhibitor	No	Exhibitor
M1	Dong-A ST	G1	Sooil Development	G16	Korea United Pharm
M2	Daewoong	G2	SK Telecome	G17	Merk Korea
МЗ	LG Chem	G3	i-SENS	G18	Hanmi Pharm
M4	Takeda Pharmaceutical	G4	Becton Dickinson	G19	Servier Korea
M5	Novo Nordisk Pharma Korea	G5	Dalimbiotech	G20	Genematrix
Мб	Handok	G6	Daewoong Bio	G21	Abbott
M7	Chong Kun Dang Pharm	G7	CJ Healthcare	G22	SK Chemicals
M8	Sanofi-Aventis Korea	G8	Daewon Pharm	G23	Celltrion
M9	Lilly Korea	G9	Huons	G24	SD Biosensor
M10	MSD Korea	G10	Hanall Bio	G25	Roche
M11	Novartis Korea	G11	Alere Healthcare	G26	YidoBio
M12	Yuhan Corporation	G12	Korea Otsuka Pharmaceutical	G27	Boryung
M13	JW Pharmaceutical	G13	Yooyoung Pharmaceutical	G28	Lameditech
M14	Boehringer Ingelheim	G14	Samwoo Medical	G29	Bukwang Pharm
M15	Ildong Pharmaceutical	G15	Medtronic Korea	G30	Health Breeze
M16	AstraZeneca				

Download ICDM2018 mobile application

All information on congress are available in the ICDM mobile application.





How to download

It can be downloaded in both Google Playstore and iOS Appstore. 'Keyword: ICDM'





Mobile application help desk

Location:

For those who have difficulties using ICDM application, please come to the Mobile Application Help Desk.

Operation time: October 11 (Thu) 16:00~18:00

> October 12 (Fri) 09:00~18:00 October 13 (Sat) 09:00~12:00

Lobby, Convention Center (1F)

Special thanks to supporters

The ICDM is grateful for the additional supports as follows.

- 50th Anniversary hood T-shirt by
- Congress bag by Othong Kun Dang
- WiFi service by Takeda
- Registration booth by Liller
- Web-book by Nebranaceutical
- Photo-wall by **(b)** LG **(17)** DONG-A ST

Diabetes & Metabolism Journal (DMJ)

Leading Journal in Asia!

(JCR Endocrinology & Metabolism category-SCIE)



2017 Impact Factor **3.710**



Diabetes & Metabolism Journal (DMJ)

2017 impact factor was 3.710 in Journal Citation Reports (JCR)

Considering your research in related areas, we cordially invite you to submit a paper to Diabetes & Metabolism Journal.

Diabetes & Metabolism Journal is an international, peer-reviewed, open access, online journal, publishing original research, reviews, and commentaries on all areas related to diabetes mellitus and metabolism. For more information, please visit the journal homepage: https://e-dmj.org/

Diabetes & Metabolism Journal indexed in Science Citation Index Expanded (SCIE) recently and has been registered in Pubmed Central.

It is indexed in PubMed, PubMed Central, SCOPUS, EMBASE, Ebsco, DOI/CrossRef, Google Scholar, KoreaMed, KoMCI, and KoreaMed Synapse.



Editorial office - Korean Diabetes Association 101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea Korea / Phone: +82-2-714-9064 Fax: +82-2-714-9084 E-mail: diabetes@kams.or.kr





www.diabetes.or.kr



































2018 International Congress of Diabetes and Metabolism

